Anavex Life Sciences Corp (STU:12X1)

€ 11.68 2.842 (32.16%) Market Cap: 985.54 Mil Enterprise Value: 858.70 Mil PE Ratio: 0 PB Ratio: 8.54 GF Score: 41/100

Q4 2024 Anavex Life Sciences Corp Earnings Call Transcript
Dec 23, 2024

€8.84 (+8.90%)

Earnings
Q3 2024 Anavex Life Sciences Corp Earnings Call Transcript
Aug 06, 2024

€6.39 (+18.94%)

Earnings
Anavex Life Sciences Corp at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q4 2023 Anavex Life Sciences Corp Earnings Call Transcript
Nov 27, 2023

€5.72 (-9.52%)

Earnings
Q3 2023 Anavex Life Sciences Corp Earnings Call Transcript
Aug 08, 2023

€6.92 (-3.11%)

Earnings
Q2 2023 Anavex Life Sciences Corp Earnings Call Transcript
May 09, 2023

€7.5 (-0.11%)

Earnings
Q1 2023 Anavex Life Sciences Corp Earnings Call Transcript
Feb 07, 2023

€10.42 (+0.75%)

Earnings
Anavex Life Sciences Corp at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Anavex Life Sciences Corp to Review ANAVEX®2-73-AD-004 Alzheimer's Disease Phase 2b/3 Call Transcript
Dec 05, 2022
Q4 2022 Anavex Life Sciences Corp Earnings Call Transcript
Nov 28, 2022

€12.3 (+14.91%)

Earnings
Q3 2022 Anavex Life Sciences Corp Earnings Call Transcript
Aug 09, 2022

€11.01 (-2.20%)

Earnings
Q2 2022 Anavex Life Sciences Corp Earnings Call Transcript
May 10, 2022

€7.29 (-4.89%)

Earnings
Anavex Life Sciences Corp at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Apr 27, 2022
Q1 2022 Anavex Life Sciences Corp Earnings Call Transcript
Feb 09, 2022

€9.7 (+2.65%)

Earnings
Anavex Life Sciences Corp to Discuss the Top-line Results from the Phase 3 AVATAR Clinical Trial of ANAVEX(®)2-73 Transcript
Feb 01, 2022
Anavex Life Sciences Corp at JPMorgan Healthcare Conference Transcript
Jan 13, 2022
Anavex Life Sciences Corp to Discuss ANAVEX®3-71 Phase 1 Top Line Data Call Transcript
Jan 10, 2022
Q4 2021 Anavex Life Sciences Corp Earnings Call Transcript
Nov 24, 2021

€16.7 (-2.91%)

Earnings
Q3 2021 Anavex Life Sciences Corp Earnings Call Transcript
Aug 12, 2021

€15.1 (-1.31%)

Earnings
Q2 2021 Anavex Life Sciences Corp Earnings Call Transcript
May 13, 2021

€8.4 (-7.18%)

Earnings
Q1 2021 Anavex Life Sciences Corp Earnings Call Transcript
Feb 11, 2021

€10.3 (-14.88%)

Earnings
Q4 2020 Anavex Life Sciences Corp Earnings Call Transcript
Dec 28, 2020

€4.5 (-7.41%)

Earnings
Anavex Life Sciences Corp. - Special Call Transcript
Oct 15, 2020
Q3 2020 Anavex Life Sciences Corp Earnings Call Transcript
Aug 06, 2020

€3.86 (-2.53%)

Earnings
Q2 2020 Anavex Life Sciences Corp Earnings Call Transcript
May 07, 2020

€3.06 (+2.00%)

Earnings
Q1 2020 Anavex Life Sciences Corp Earnings Call Transcript
Feb 06, 2020

€3.38 (+1.20%)

Earnings
Q4 2019 Anavex Life Sciences Corp Earnings Call Transcript
Dec 16, 2019

€2.16 (-0.92%)

Earnings
Q3 2019 Anavex Life Sciences Corp Earnings Call Transcript
Aug 07, 2019

€2.2 (+7.84%)

Earnings
Q2 2019 Anavex Life Sciences Corp Earnings Call Transcript
May 08, 2019

€2.65 (-4.68%)

Earnings
Q1 2019 Anavex Life Sciences Corp Earnings Call Transcript
Feb 07, 2019

€1.75 (-1.13%)

Earnings

Anavex Life Sciences Corp to Discuss the Top-line Results from the Phase 3 AVATAR Clinical Trial of ANAVEX(®)2-73 Transcript

Feb 01, 2022 / 01:30PM GMT

Release Date Price: €11.5 (+1.77%)

Transcript 10-Q

Clint Tomlinson

Anavex Life Sciences Corp. - VP of Corporate

Good morning, and welcome, everyone. Welcome to the Anavex Life Sciences AVATAR ANAVEX 2-73 Phase III Top Line Data Conference Call. My name is Clint Tomlinson, and I'll be your host for today's call. (Operator Instructions) Please note, this conference is being recorded. The call will be available for replay on Anavex's website at www.anavex.com.

With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Dr. Ed Hammond, Chief Medical Officer; and Walter E. Kaufmann, Chief Scientific Officer.

Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company filings with the SEC. This includes, without limitation, the company's Forms 10-K and 10-Q, which identify specific factors that may cause actual

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.